References - Pulmonary Infections in Adults

Thomas M. File, Jr; Julio A. Ramirez

Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):E45-E67.

File TM, Ramirez JA. Community-acquired pneumonia. New Engl J Med. 2023;389(7):632-641.

Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.

McDermott KW, Roemer M. Most frequent principal diagnoses for inpatient stays in U.S. hospitals, 2018. Healthcare cost and utilization project (HCUP) statistical briefs. https://www.ncbi.nlm.nih.gov/books/NBK573113/

Murphy SL, Kochanek KD, Xu J, et al. Centers for Disease Control and Prevention. Mortality in the United States, 2020 Key findings data from the National Vital Statistics system. https://www.cdc.gov/nchs/products/index.htm

Ramirez JA, Wiemken TL, Peyrani P, et al.; University of Louisville Pneumonia Study Group. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806-1812.

File TM, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-141.

Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-250.

Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-141.

Faner R, Sibila O, Agustí A, et al. The microbiome in respiratory medicine: current challenges and future perspectives. Eur Respir J. 2017;49(4):1602086.

Jain S, Self WH, Wunderink RG, et al.; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427.

Gadsby NJ, Musher DM. The microbial etiology of community-acquired pneumonia in adults: from classical bacteriology to host transcriptional signatures. Clin Microbiol Rev. 2022;35(4):e0001522.

Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50(2):202-209.

File TM, Marrie TJ. Does empiric therapy for atypical pathogens improve outcomes for patients with CAP? Infect Dis Clin North Am. 2013;27(1):99-114.

Arnold FW, Summersgill JT, Lajoie AS, et al.; Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175(10):1086-1093.

Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis. 2011;52(suppl 4):S346-S350.

Centers for Disease Control and Prevention. Antibiotic-resistant Streptococcus pneumoniae. https://www.cdc.gov/pneumococcal/php/drug-resistance/index.html

Henig O, Kaye KS. Bacterial pneumonia in older adults. Infect Dis Clin North Am. 2017;31(4):689-713.

Xirouchaki N, Magkanas E, Vaporidi K, et al. Lung ultrasound in critically ill patients: comparison with bedside chest radiography. Intensive Care Med. 2011;37(9):1488-1493.

Díaz-Gómez JL, Mayo PH, Koenig SJ. Point-of-care ultrasonography. N Engl J Med. 2021;385(17):1593-1602.

Bishop BM, Bon JJ, Trienski TL, et al. Effect of introducing procalcitonin on antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit. Ann Pharmacother. 2014;48(5):577-583.

Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017(10):CD007498.

Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019;57(9):1308-1318.

Rhee C, Mansour MK. Procalcitonin use in lower respiratory tract infections. UpToDate. https://sso.uptodate.com/contents/procalcitonin-use-in-lower-respiratory-tract-infections

Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-382.

File TM. New diagnostic tests for pneumonia: what is their role in clinical practice? Clin Chest Med. 2011;32(3):417-430.

Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA’s diagnostics committee. Clin Infect Dis. 2020;71(10):2744-2751.

Burillo A, Candel FJ, Canut-Blasco A. Value of syndromic panels in the management of severe community-acquired pneumonia. Rev Esp Quimioter. 2022;35(suppl 1):15-20.

Gentilotti E, De Nardo P, Cremonini E, et al. Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(1):13-22.

Falsey AR, Branche AR, Croft DP, et al. Real-life assessment of Bio-Fire FilmArray pneumonia panel in adults hospitalized with respiratory illness. J Infect Dis. 2024;229(1):214-222.

Parente DM, Cunha CB, Mylonakis E, et al. The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. Clin Infect Dis. 2018;67(1):1-7.

Gupta V, Yu KC, Schranz J, et al. A multicenter evaluation of the US prevalence and regional variation in macrolide-resistant S. pneumoniae in ambulatory and hospitalized adult patients in the United States. Open Forum Infect Dis. 2021;8(7):ofab063.

File TM, Goldberg L, Das A, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III lefamulin evaluation against pneumonia (LEAP 1) trial. Clin Infect Dis. 2019;69(11):1856-1867.

Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517-527.

Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023;49(6):615-632.

Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019;380(7):651-663.

Infectious Diseases Society of America. IDSA Guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/COVID19guidelines

Saleem N, Kulkarni A, Snow TAC, et al. Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia. Chest. 2023;163(3):484-497.

Bergmann F, Pracher L, Sawodny R, et al. Efficacy and safety of corticosteroid therapy for community-acquired pneumonia. Clin Infect Dis. 2023;77(12):1704-1713.

Dequin PF, Meziani F, Quenot JP, et al.; CRICS-TriGGERSep Network. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023;388(21):1931-1941.

Lansbury L, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019(2):CD010406.

Parody R, Martino R, Sánchez F, et al. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation. Am J Hematol. 2009;84(9):571-578.

van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax. 2005;60(8):672-678.

Viasus D, Simonetti AF, Garcia-Vidal C, et al. Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. J Antimicrob Chemother. 2017;72(2):547-553.

Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1995;155(12):1273-1276.

Aliberti S, Zanaboni AM, Wiemken T, et al. Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. Eur Respir J. 2013;42(3):742-749.

Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs. 2008;68(13):1841-1854.

el Moussaoui R, de Borgie CAJM, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ. 2006;332(7554):1355.

Dinh A, Ropers J, Duran C, et al.; Pneumonia Short Treatment (PTC) Study Group. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021;397(10280):1195-1203.

Tak HJ, Chen LW, Wilson FA, et al. Post-discharge services for different diagnoses than index hospitalization predict decreased 30-day readmissions among Medicare beneficiaries. J Gen Intern Med. 2019;34(9):1766-1774.

Krist AH, Davidson KW, Mangione CM, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970.

Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 1999;159(9):970-980.

Menéndez R, Torres A, Zalacaín R, et al.; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004;59(11):960-965.

Aliberti S, Amir A, Peyrani P, et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest. 2008;134(5):955-962.

Feldman C, Anderson R. Pneumonia as a systemic illness. Curr Opin Pulm Med. 2018;24(3):237-243.

Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008;47(2):182-187.

Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-274.

Rivero-Calle I, Cebey-López M, Pardo-Seco J, et al. Lifestyle and comorbid conditions as risk factors for community-acquired pneumonia in outpatient adults (NEUMO-ES-RISK project). BMJ Open Respir Res. 2019;6(1):e000359.

Centers for Disease Control and Prevention. Adult immunization schedule by age. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-schedule-vaccines.html

Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111.

Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J. 2017;50(3):1700582.

Magill SS, O’Leary E, Janelle SJ, et al. Changes in prevalence of health care-associated infections in U.S. hospitals. N Engl J Med. 2018;379(18):1732-1744.

Modi AR, Kovacs CS. Hospital-acquired and ventilator-associated pneumonia: diagnosis, management, and prevention. Cleve Clin J Med. 2020;87(10):633-639.

Candel FJ, Salavert M, Estella A, et al. Ten issues to update in nosocomial or hospital-acquired pneumonia: an expert review. J Clin Med. 2023;12(20):6526.

Motowski H, Ilges D, Hampton N, et al. Determinants of mortality for ventilated hospital-acquired pneumonia and ventilator-associated pneumonia. Crit Care Explor. 2023;5(3):e0867.

Luyt CE, Hékimian G, Koulenti D, et al. Microbial cause of ICU-acquired pneumonia. Curr Opin Crit Care. 2018;24(5):332-338.

Klompas M, Branson R, Cawcutt K, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and non-ventilator hospital-acquired pneumonia in acute-care hospitals: 2022 update. Infect Control Hosp Epidemiol. 2022;43(6):687-713.

Zilberberg MD, Nathanson BH, Puzniak LA, et al. Descriptive epidemiology and outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2012-2019. Crit Care Med. 2022;50(3):460-468.

Morrow L, Kollef M. Hospital-acquired pneumonia. In: Jong EC, Stevens DL, eds. Netter’s Infectious Diseases. 2nd ed. Elsevier; 2022.

Ferrer M, Torres A. Epidemiology of ICU-acquired pneumonia. Curr Opin Crit Care. 2018;24(5):325-331.

Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest. 1988;93(2):318-324.

Kim BG, Kang M, Lim J, et al. Comprehensive risk assessment for hospital-acquired pneumonia. BMC Pulm Med. 2022;22(1):21.

Rautaporras N, Furuholm J, Uittamo J, et al. Deep odontogenic infections-identifying risk factors for nosocomial pneumonia. Clin Oral Investig. 2021;25(4):1925-1932.

Huang HB, Jiang W, Wang CY, et al. Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition. Crit Care. 2018;22(1):20.

Barbateskovic M, Marker S, Granholm A, et al. Stress ulcer prophylaxis with proton pump inhibitors or histamin-2 receptor antagonists in adult intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2019;45(2):143-158.

File TM. Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines. Clin Infect Dis. 2010;51(suppl 1):S42-S47.

Fàbregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited. Thorax. 1999;54(10):867-873.

Grossman RF, Fein A. Evidence-based assessment of diagnostic tests for ventilator-associated pneumonia. Executive summary. Chest. 2000;117(4 suppl 2):177S-181S.

Fernando SM, Tran A, Cheng W, et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients—a systematic review and meta-analysis. Intensive Care Med. 2020;46(6):1170-1179.

Weber DJ, Rutala WA, Sickbert-Bennett EE, et al. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28(7):825-831.

Zilberberg MD, Nathanson BH, Puzniak LA, et al. Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014-2019. Infect Control Hosp Epidemiol. 2022;43(3):277-283.

Agarwal S, Abell V, File TM. Nosocomial (health care-associated) Legionnaire’s disease. Infect Dis Clin North Am. 2017;31(1):155-165.

Vonberg RP, Gastmeier P. Nosocomial aspergillosis in outbreak settings. J Hosp Infect. 2006;63(3):246-254.

Zilberbeg MD, Khan I, Shorr AF. Respiratory viruses in nosocomial pneumonia: an evolving paradigm. Viruses. 2023;15(8):1676.

Luyt CE, Bréchot N, Chastre J. What role do viruses play in nosocomial pneumonia? Curr Opin Infect Dis. 2014;27(2):194-199.

Du Q, Zhang D, Hu W, et al. Nosocomial infection of COVID19. Int J Mol Med. 2021;47(4):31.

Centers for Disease Control and Prevention. Antimicrobial resistance threats in the United States, 2021-2022. https://www.cdc.gov/antimicrobial-resistance/data-research/threats/update-2022.html

Zasowski EJ, Bassetti M, Blasi F, et al. A systematic review of the effect of delayed appropriate antibiotic treatment on the outcomes of patients with severe bacterial infections. Chest. 2020;158(3):929-938.

Hanson KE, Azar MM, Banerjee R, et al. Molecular testing for acute respiratory tract infections. Clin Infect Dis. 2020;71(10):2744-2751.

Stafylaki D, Maraki S, Vaporidi K, et al. Impact of molecular syndromic diagnosis of severe pneumonia in the management of critically ill patients. Microbiol Spectr. 2022;10(5):e0161622.

Muscedere JG, Shorr AF, Jiang X, et al. The adequacy of timely empiric antibiotic therapy for ventilator-associated pneumonia: an important determinant of outcome. J Crit Care. 2012;27(3):322.e7-322.e14.

Kollef MH, Shorr AF, Bassetti M, et al. Timing of antibiotic therapy in the ICU. Crit Care. 2021;25(1):360.

Kuti EL, Patel AA, Coleman CI. Impact of inappropriate antibiotic therapy on mortality in patients with ventilator-associated pneumonia and blood stream infection: a meta-analysis. J Crit Care. 2008;23(1):91-100.

Humphries RM. Updated aminoglycoside breakpoints for Enterobacterales and Pseudomonas aeruginosa. Clinical and Laboratory Standards Institute. https://clsi.org/about/blog/ast-news-update-june-2023-new-clsi-m100-ed33-updated-aminoglycoside-breakpoints-for-enterobacterales-and-pseudomonas-aeruginosa/

Gamazo JJ, Candel FJ, Del Castillo JG. Nosocomial pneumonia. Rev Esp Quimioter. 2023;36(suppl 1):9-14.

Bassetti M, Mularoni A, Giacobbe DR, et al. New antibiotics for hospital-acquired pneumonia and ventilator-associated pneumonia. Semin Respir Crit Care Med. 2022;43(2):280-294.

Shen Y, Kuti JL. Optimizing antibiotic dosing regimens for nosocomial pneumonia. Expert Opin Drug Metab Toxicol. 2023;19(1):13-25.

Parente DM, Cunha CB, Mylonakis E, et al. The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia. Clin Infect Dis. 2018;67(1):1-7.

Ewig S. Nosocomial pneumonia: de-escalation is what matters. Lancet Infect Dis. 2011;11(3):155-157.

Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129(5):1210-1218.

Eachempati SR, Hydo LJ, Shou J, et al. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? J Trauma. 2009;66(5):1343-1348.

Ranzani OT, Ferrer M, Esperatti M, et al. Association between systemic corticosteroids and outcomes of intensive care unit–acquired pneumonia. Crit Care Med. 2012;40(9):2552-2561.

Chastre J, Wolff M, Fagon JY, et al.; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588-2598.

Pugh R, Grant C, Cooke RPD, et al. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev. 2015(8):CD007577.

Dimopoulos G, Poulakou G, Pneumatikos IA, et al. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest. 2013;144(6):1759-1767.

Chastre J, Luyt CE. Optimising the duration of antibiotic therapy for ventilator-associated pneumonia. Eur Respir Rev. 2007;16(103):40-44.

Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019;57(9):1308-1318.

Wang R, Zhang J, He M, et al. Procalcitonin as a biomarker of nosocomial pneumonia in aneurysmal subarachnoid hemorrhage patients treated in neuro-ICU. Clin Neurol Neurosurg. 2023;231:107870.

Wirz Y, Meier MA, Bouadma L, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. Crit Care. 2018;22(1):191.

Wunderink RG. Welkommen to our world. Emergence of antibiotic resistance with selective decontamination of the digestive tract. Am J Respir Crit Care Med. 2010;181(5):426-427.

Kollef MH, Micek ST. Rational use of antibiotics in the ICU: balancing stewardship and clinical outcomes. JAMA. 2014;312(14):1403-1404.

Di Pasquale MF, Sotgiu G, Gramegna A, et al.; GLIMP Investigators. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis. 2019;68(9):1482-1493.

Jain S, Self WH, Wunderink RG, et al.; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415-427.

Sousa D, Justo I, Domínguez A, et al. Community-acquired pneumonia in immunocompromised older patients: incidence, causative organisms and outcome. Clin Microbiol Infect. 2013;19(2):187-192.

Ramirez JA, Chandler TR, Furmanek SP, et al.; Louisville CAP in the Immunocompromised Study Group. Community-acquired pneumonia in the immunocompromised host: epidemiology and outcomes. Open Forum Infect Dis. 2023;10(11):ofad565.

Centers for Disease Control and Prevention. People who are immunocompromised. https://archive.cdc.gov/www_cdc_gov/coronavirus/2019-ncov/need-extra-precautions/people-who-are-immunocompromised.html

Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest. 2020;158(5):1896-1911.

Harpaz R, Dahl RM, Dooling KL. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016;316(23):2547-2548.

Jenkinson PW, Plevris N, Siakavellas S, et al. Temporal trends in surgical resection rates and biologic prescribing in Crohn’s disease: a population-based cohort study. J Crohns Colitis. 2020;14(9):1241-1247.

Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.

Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659-667.

United Network for Organ Sharing. OPTN Metrics. https://insights.unos.org/OPTN-metrics/

Gonzalez C, Johnson T, Rolston K, et al. Predicting pneumonia mortality using CURB-65, PSI, and patient characteristics in patients presenting to the emergency department of a comprehensive cancer center. Cancer Med. 2014;3(4):962-970.

Sanders KM, Marras TK, Chan CKN. Pneumonia severity index in the immunocompromised. Can Respir J. 2006;13(2):89-93.

National Institutes of Health, HIV Medicine Association, Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/pneumocystis?view=full

Wieruszewski PM, Barreto JN, Frazee E, et al. Early corticosteroids for pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest. 2018;154(3):636-644.

Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis. Clin Infect Dis. 2009;48(12):1743-1751.

Restrepo A, Clark NM. Nocardia infections in solid organ transplantation: guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation. Clin Transplant. 2019;33(9):e13509.

Mirouse A, Vignon P, Piron P, et al. Severe varicella-zoster virus pneumonia: a multicenter cohort study. Crit Care. 2017;21(1):137.

Travi G, Pergam SA. Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J Intensive Care Med. 2014;29(4):200-212.

Lodding IP, Schultz HH, Jensen JU, et al. Cytomegalovirus viral load in bronchoalveolar lavage to diagnose lung transplant associated CMV pneumonia. Transplantation. 2018;102(2):326-332.

Machado CM, Dulley FL, Boas LS, et al. CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy. Bone Marrow Transplant. 2000;26(4):413-417.

Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev. 2004;17(1):208-217.

Patrat-Delon S, Gangneux JP, Lavoué S, et al. Correlation of parasite load determined by quantitative PCR to clinical outcome in a heart transplant patient with disseminated toxoplasmosis. J Clin Microbiol. 2010;48(7):2541-2545.

Sperling S, Dahl VN, Fløe A. Lung abscess: an update on the current knowledge and call for future investigations. Curr Opin Pulm Med. 2024;30(3):229-234.

Kuhajda I, Zarogoulidis K, Tsirgogianni K, et al. Lung abscess-etiology, diagnostic and treatment options. Ann Transl Med. 2015;3(13):183.

Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019;380(7):651-663.

Lorber B, Swenson RM. Bacteriology of aspiration pneumonia. A prospective study of community- and hospital-acquired cases. Ann Intern Med. 1974;81(3):329-331.

Smith DT. Experimental aspiratory abscess. Arch Surg. 1927;14(1):231-239.

File TM, Fass RJ, Prior RB. Response of mice to transtracheal pulmonary inoculation of anaerobic bacteria. Lab Anim. 1982;16(4):348-350.

Kannangara DW, Thadepalli H, Bach VT, et al. Animal model for anaerobic lung abscess. Infect Immun. 1981;31(2):592-597.

Shinzato T, Saito A. A mechanism of pathogenicity of “Streptococcus milleri group” in pulmonary infection: synergy with an anaerobe. J Med Microbiol. 1994;40(2):118-123.

Eftimiadi C, Tonetti M, Cavallero A, et al. Short-chain fatty acids produced by anaerobic bacteria inhibit phagocytosis by human lung phagocytes. J Infect Dis. 1990;161(1):138-142.

Bartlett JG, Gorbach SL, Finegold SM. The bacteriology of aspiration pneumonia. Am J Med. 1974;56(2):202-207.

Wang JL, Chen KY, Fang CT, et al. Changing bacteriology of adult community-acquired lung abscess in Taiwan: Klebsiella pneumoniae versus anaerobes. Clin Infect Dis. 2005;40(7):915-922.

Takayanagi N, Kagiyama N, Ishiguro T, et al. Etiology and outcome of community-acquired lung abscess. Respiration. 2010;80(2):98-105.

Maitre T, Ok V, Calin R, et al. Pyogenic lung abscess in an infectious disease unit: a 20-year retrospective study. Ther Adv Respir Dis. 2021;15:17534666211003012.

Montméat V, Bonny V, Urbina T, et al. Epidemiology and clinical patterns of lung abscesses in ICU: A French multicenter retrospective study. Chest. 2024;165(1):48-57.

Rolston KVI, Nesher L. Post-obstructive pneumonia in patients with cancer: a review. Infect Dis Ther. 2018;7(1):29-38.

Hsu-Kim C, Hoag JB, Cheng GS, et al. The microbiology of postobstructive pneumonia in lung cancer patients. J Bronchology Interv Pulmonol. 2013;20(3):266-270.

Yazbeck MF, Dahdel M, Kalra A, et al. Lung abscess: update on microbiology and management. Am J Ther. 2014;21(3):217-221.

Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. 2019;200(7):e45-e67.

Boucher B, Virlan D, Buddharaju V, et al. Conservative approach and management of complicated lung abscess. Cureus. 2022;14(11):e31910.

Chiang PC, Lin CY, Hsu YC, et al. Early drainage reduces the length of hospital stay in patients with lung abscess. Front Med (Lausanne). 2023;10:1206419.

Kelogrigoris M, Tsagouli P, Stathopoulos K, et al. CT-guided percutaneous drainage of lung abscesses: review of 40 cases. JBR-BTR. 2011;94(4):191-195.

Lee JH, Hong H, Tamburrini M, et al. Percutaneous transthoracic catheter drainage for lung abscess: a systematic review and meta-analysis. Eur Radiol. 2022;32(2):1184-1194.

Soni NJ, Franco R, Velez MI, et al. Ultrasound in the diagnosis and management of pleural effusions. J Hosp Med. 2015;10(12):811-816.

Wilcox ME, Chong CAKY, Stanbrook MB, et al. Does this patient have an exudative pleural effusion? The Rational Clinical Examination Systematic Review. JAMA. 2014;311(23):2422-2431.

Porcel JM, Esquerda A, Vives M, et al. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014;50(5):161-165.

Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Chest. 1997;111(4):970-980.

Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc. 2006;3(1):75-80.

Li P, An J, Wang S, et al. Incidence and prognostic role of pleural effusion in patients with pulmonary embolism: a systematic review and meta-analysis. J Clin Med. 2023;12(6):2315.

Redden MD, Chin TY, van Driel ML. Surgical versus non-surgical management for pleural empyema. Cochrane Database Syst Rev. 2017(3):CD010651.

Continue Reading